Analysts Issue Forecasts for RYTM FY2026 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - HC Wainwright issued their FY2026 earnings estimates for shares of Rhythm Pharmaceuticals in a research note issued on Monday, March 3rd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($1.49) per share for the year. HC Wainwright currently has a "Buy" rating and a $70.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals' current full-year earnings is ($4.32) per share.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $41.83 million during the quarter, compared to analyst estimates of $38.48 million.

A number of other research firms have also recently issued reports on RYTM. The Goldman Sachs Group lifted their price target on shares of Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the company a "buy" rating in a research note on Thursday, December 5th. Jefferies Financial Group assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Thursday, January 2nd. They issued a "buy" rating and a $80.00 price target on the stock. Oppenheimer assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Friday, December 20th. They set an "outperform" rating and a $76.00 target price on the stock. Morgan Stanley reaffirmed an "overweight" rating and set a $72.00 target price on shares of Rhythm Pharmaceuticals in a research note on Friday. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 target price on shares of Rhythm Pharmaceuticals in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $69.31.

Remove Ads

Rhythm Pharmaceuticals Stock Performance

Rhythm Pharmaceuticals stock traded down $0.85 during trading on Wednesday, reaching $50.79. The company had a trading volume of 637,652 shares, compared to its average volume of 491,829. The firm's 50-day simple moving average is $56.53 and its 200 day simple moving average is $54.48. Rhythm Pharmaceuticals has a 1-year low of $35.17 and a 1-year high of $68.58. The firm has a market capitalization of $3.21 billion, a PE ratio of -11.73 and a beta of 2.30.

Institutional Trading of Rhythm Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of RYTM. Creative Planning purchased a new stake in Rhythm Pharmaceuticals in the 3rd quarter valued at about $450,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Rhythm Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,211 shares of the company's stock valued at $114,000 after buying an additional 391 shares during the period. Harbor Capital Advisors Inc. increased its stake in Rhythm Pharmaceuticals by 19.5% during the third quarter. Harbor Capital Advisors Inc. now owns 41,368 shares of the company's stock worth $2,167,000 after purchasing an additional 6,741 shares during the period. Principal Financial Group Inc. increased its stake in Rhythm Pharmaceuticals by 241.9% during the third quarter. Principal Financial Group Inc. now owns 32,586 shares of the company's stock worth $1,707,000 after purchasing an additional 23,054 shares during the period. Finally, Victory Capital Management Inc. increased its stake in Rhythm Pharmaceuticals by 158.0% during the third quarter. Victory Capital Management Inc. now owns 18,186 shares of the company's stock worth $953,000 after purchasing an additional 11,137 shares during the period.

Insider Activity

In related news, CAO Christopher Paul German sold 635 shares of the business's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total value of $36,334.70. Following the sale, the chief accounting officer now directly owns 2,070 shares in the company, valued at approximately $118,445.40. The trade was a 23.48 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joseph Shulman sold 1,281 shares of the business's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $59.43, for a total transaction of $76,129.83. Following the completion of the sale, the insider now owns 2,657 shares in the company, valued at approximately $157,905.51. This trade represents a 32.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,787 shares of company stock valued at $1,901,443. 5.60% of the stock is currently owned by insiders.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.